Immunocore Holdings plc (IMCR) Insider Trading

Last 12 months

Insiders sold $5.63M and bought nothing on the open market.

89% of the selling was scheduled in advance under 10b5-1 plans. CHIEF EXECUTIVE OFFICER Bahija Jallal sold $371k on Feb 18, 48% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$5.63M

0 buys · 7 sales

Under a 10b5-1 plan

89%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

None

in the last two years

Get an email when IMCR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 18	Tina Amber St Leger CHIEF HR OFFICER	SoldNo plan	1,000	$32.35	$32k	47%	Form 4
Feb 18	David M Berman HEAD OF R&D	SoldNo plan	5,965	$32.35	$193k	50%	Form 4
Feb 18	John Goll SVP, FINANCE & CAO	SoldNo plan	698	$32.35	$23k	52%	Form 4
Feb 18	Bahija Jallal CHIEF EXECUTIVE OFFICER	SoldNo plan	11,474	$32.35	$371k	48%	Form 4
Dec 4, 2025 – Dec 5, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan 2 parts	31,913	$40.26 average	$1.28M	100%	Form 4
Nov 26, 2025 – Nov 28, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan 2 parts	74,925	$40.12 average	$3.01M	100%	Form 4
Nov 24, 2025 – Nov 25, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan 2 parts	18,120	$40.03 average	$725k	100%	Form 4
Sep 30, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan	61,849	$35.23	$2.18M	100%	Form 4
Sep 12, 2025 – Sep 15, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan 3 parts	22,732	$35.66 average	$811k	100%	Form 4
Sep 10, 2025 – Sep 11, 2025	David M Berman HEAD OF R&D	Sold10b5-1 plan 3 parts	50,419	$36.20 average	$1.82M	100%	Form 4
Mar 17, 2025	667, L.p. Large holder	Bought 4 parts	807,338	$29.72 average	$24M	60%	Form 4

Feb 18No plan
Tina Amber St Leger
CHIEF HR OFFICER · sold 1,000 at $32.35
$32k
47% of stake
Feb 18No plan
David M Berman
HEAD OF R&D · sold 5,965 at $32.35
$193k
50% of stake
Feb 18No plan
John Goll
SVP, FINANCE & CAO · sold 698 at $32.35
$23k
52% of stake
Feb 18No plan
Bahija Jallal
CHIEF EXECUTIVE OFFICER · sold 11,474 at $32.35
$371k
48% of stake
Dec 4, 2025 – Dec 5, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 31,913 at avg $40.26
$1.28M
100% of stake
Nov 26, 2025 – Nov 28, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 74,925 at avg $40.12
$3.01M
100% of stake
Nov 24, 2025 – Nov 25, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 18,120 at avg $40.03
$725k
100% of stake
Sep 30, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 61,849 at $35.23
$2.18M
100% of stake
Sep 12, 2025 – Sep 15, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 22,732 at avg $35.66
$811k
100% of stake
Sep 10, 2025 – Sep 11, 202510b5-1 plan
David M Berman
HEAD OF R&D · sold 50,419 at avg $36.20
$1.82M
100% of stake
Mar 17, 2025
667, L.p.
Large holder · bought 807,338 at avg $29.72
$24M
60% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IMCR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

TWSTTwist Bioscience Corporation

KRYSKrystal Biotech Inc.

NVAXNovavax Inc.

MGTXMeiraGTx Holdings plc

ADMAAdma Biologics Inc.

DNLIDenali Therapeutics Inc.

ADPTAdaptive Biotechnologies Corporation

VCELVericel Corporation

Spot a number that looks wrong? Check it in IMCR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IMCR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.